Rani Therapeutics Holdings, Inc.
RANI · XNASCIK 1856725fmd_1YD86RQCAADM3NBS9DMJHQ98PVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 3 | 0 | 0 | 1 | 2 |
| Research and development | 12 | 26 | 37 | 40 | 27 | 20 |
| Total operating expenses | (17) | 54 | 63 | 66 | 54 | 40 |
| Operating income | (17) | (52) | (63) | (66) | (53) | (38) |
| Interest expense | 0 | 0 | 1 | 5 | 5 | 3 |
| Interest and investment income | 0 | 0 | 1 | 3 | 2 | 1 |
| Income before taxes | (17) | (53) | (63) | (68) | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (17) | (53) | (63) | (68) | – | – |
| Net income | (17) | (8) | (31) | (34) | (30) | (30) |